eIF

阻害剤の選択性比較

カタログ番号	製品カタログ	溶解度(25°C)
カタログ番号	製品カタログ	水	DMSO	アルコール
S2923	Salubrinal	<1 mg/mL	95 mg/mL	'2 mg/mL
S7369	4EGI-1	<1 mg/mL	90 mg/mL	<1 mg/mL
S7437	Sal003	<1 mg/mL	93 mg/mL	<1 mg/mL
S0706	ISRIB	<1 mg/mL	10 mg/mL	''<1 mg/mL
S6533	Briciclib	<1 mg/mL	95 mg/mL	'<1 mg/mL
S7428	Rocaglamide	<1 mg/mL	100 mg/mL	'''''10 mg/mL
S2961	GC7 Sulfate	3 mg/mL	<1 mg/mL	''''<1 mg/mL
S9668	PKR-IN-C16	<1 mg/mL	13 mg/mL	'''''''<1 mg/mL
S7370	4E1RCat	<1 mg/mL	96 mg/mL	<1 mg/mL
S8275	Tomivosertib (eFT-508)	<1 mg/mL	13 mg/mL	<1 mg/mL
S8181	SBI-0640756	<1 mg/mL	80 mg/mL	<1 mg/mL

eIF製品

All (11) eIF阻害剤(11)

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2923	Salubrinal Salubrinal is a selective inhibitor of eIF2α dephosphorylation and inhibits ER stress-mediated apoptosis with EC50 of ~15 μM in a cell-free assay.	Nat Commun, 2021, 12(1):1589 Int J Mol Sci, 2021, 22(7)3501 Adv Sci (Weinh), 2020, 7(22):2002747	AngII (30 minutes)-induced Akt activation was attenuated by the ER stress inhibitors 4-PBA (5 mM, 2 hours), TUDCA (300 µg/ml, 1 hour), and salubrinal (30 µM, 1 hour) (n=5; *P<0.01 versus con, #P<0.05 versus Ang)
S7369	4EGI-1 4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM.	FASEB J, 2021, 35(5):e21445 Mol Pharmacol, 2021, 99(1):1-16 J Cell Mol Med, 2021, 10.1111/jcmm.16307	Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; , P < 0.05; , P < 0.01; **, P < 0.001.
S7437	Sal003 Sal003 is a potent and cell-permeable eIF-2α phosphatase inhibitor.
S0706^新	ISRIB ISRIB is an integrated stress response (ISR) inhibitor that potently reverses the effects of eukaryotic initiation factor 2α (eIF2α) phosphorylation with IC50 of 5 nM.
S6533	Briciclib Briciclib (ON-014185) is a water soluble derivative of ON-013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).
S7428^新	Rocaglamide Rocaglamide (Roc-A), isolated from Aglaia species, is a potent inhibitor of heat shock factor 1 (HSF1) activation with IC50 of ~50 nM for HSF1. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also inhibits NF-κB activity. Rocaglamide exhibits anti-tumor activity.
S2961^新	GC7 Sulfate GC7 (N1-guanyl-1,7-diaminoheptane) Sulfate is an inhibitor of deoxyhypusine synthase (DHPS). GC7 inhibits Neuroblastoma (NB) cell proliferation in a dose-dependent manner, through induction of the cell cycle inhibitor p21 and reduction of total and phosphorylated Rb proteins.
S9668^新	PKR-IN-C16 PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
S7370	4E1RCat 4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.	J Cell Mol Med, 2021, 10.1111/jcmm.16307 Int J Ophthalmol, 2020, 13(1):7-10 Sci Transl Med, 2019, 11(503)	Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
S8275	Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Clin Invest, 2021, 140752 Elife, 2020, 9e60151 Cell Rep Med, 2020, 1(8):100131
S8181	SBI-0640756 SBI-0640756 is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-kB signaling.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2923	Salubrinal Salubrinal is a selective inhibitor of eIF2α dephosphorylation and inhibits ER stress-mediated apoptosis with EC50 of ~15 μM in a cell-free assay.	Nat Commun, 2021, 12(1):1589 Int J Mol Sci, 2021, 22(7)3501 Adv Sci (Weinh), 2020, 7(22):2002747	AngII (30 minutes)-induced Akt activation was attenuated by the ER stress inhibitors 4-PBA (5 mM, 2 hours), TUDCA (300 µg/ml, 1 hour), and salubrinal (30 µM, 1 hour) (n=5; *P<0.01 versus con, #P<0.05 versus Ang)
S7369	4EGI-1 4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with K_D of 25 μM.	FASEB J, 2021, 35(5):e21445 Mol Pharmacol, 2021, 99(1):1-16 J Cell Mol Med, 2021, 10.1111/jcmm.16307	Hep3B and PC3 cells were treated with 50 μmol/L 4EGI-1 or 5 μmol/L ABT alone or their combination for 48 hours, and then the cell viability was examined by CCK-8 assay. p, phosphorylated; t, total; T, Thr; S, Ser; , P < 0.05; , P < 0.01; **, P < 0.001.
S7437	Sal003 Sal003 is a potent and cell-permeable eIF-2α phosphatase inhibitor.
S0706^新	ISRIB ISRIB is an integrated stress response (ISR) inhibitor that potently reverses the effects of eukaryotic initiation factor 2α (eIF2α) phosphorylation with IC50 of 5 nM.
S6533	Briciclib Briciclib (ON-014185) is a water soluble derivative of ON-013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).
S7428^新	Rocaglamide Rocaglamide (Roc-A), isolated from Aglaia species, is a potent inhibitor of heat shock factor 1 (HSF1) activation with IC50 of ~50 nM for HSF1. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also inhibits NF-κB activity. Rocaglamide exhibits anti-tumor activity.
S2961^新	GC7 Sulfate GC7 (N1-guanyl-1,7-diaminoheptane) Sulfate is an inhibitor of deoxyhypusine synthase (DHPS). GC7 inhibits Neuroblastoma (NB) cell proliferation in a dose-dependent manner, through induction of the cell cycle inhibitor p21 and reduction of total and phosphorylated Rb proteins.
S9668^新	PKR-IN-C16 PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
S7370	4E1RCat 4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.	J Cell Mol Med, 2021, 10.1111/jcmm.16307 Int J Ophthalmol, 2020, 13(1):7-10 Sci Transl Med, 2019, 11(503)	Immunoblot analysis of IRF7 in wild-type FL-pDCs pretreated with 50 µM 4E1Rcat (4E1R) or DMSO 6 h following stimulation with CpG ODN (1 µM) for 15 min.
S8275	Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Clin Invest, 2021, 140752 Elife, 2020, 9e60151 Cell Rep Med, 2020, 1(8):100131
S8181	SBI-0640756 SBI-0640756 is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-kB signaling.